Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

BackgroundFaricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs) in real-world settings is crucial. This study e...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Chang-Zhu He, Qin Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Subjects:	faricimab adverse events FAERS database disproportionality pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1521358/full